BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on Erwinase® 10.000 IU/vial, powder for solution for injection: information on temporary shortage

2017.01.31

Active substance: crisantaspase

The company Jazz Pharmaceuticals Germany GmbH is circulating information on the fact that, due to a temporary shortage, Erwinase® 10.000 I.U./vial powder for solution for injection is currently only available under consideration of the provisions of Section 73 (3) AMG.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 261KB, File is accessible